Adage Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Adage Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.75M	Sell	50,000 -90,000	-64%	-$7.1M	0.01%	796
2025 Q4	$11.1M	Sell	140,000 -1,175,000	-89%	-$88.5M	0.02%	643
2025 Q3	$86M	Sell	1,315,000 -2,485,000	-65%	-$121M	0.14%	152
2025 Q2	$150M	Buy	3,800,000 +2,724,400	+253%	+$89.2M	0.25%	74
2025 Q1	$32.5M	Buy	1,075,600 +800,600	+291%	+$26.2M	0.06%	313
2024 Q4	$9.61M	Sell	275,000 -225,000	-45%	-$8.41M	0.02%	619
2024 Q3	$20M	Sell	500,000 -300,000	-38%	-$14M	0.04%	450
2024 Q2	$38.1M	Sell	800,000 -200,000	-20%	-$8.2M	0.07%	276
2024 Q1	$43.4M	Sell	1,000,000 -385,300	-28%	-$18.4M	0.08%	256
2023 Q4	$70.1M	Buy	1,385,300 +318,300	+30%	+$15.2M	0.15%	154
2023 Q3	$48.4M	Buy	+1,067,000	New	+$44M	0.11%	204

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners's IONS Position: Q1 2026 in Review

Adage Capital Partners reduced its Ionis Pharmaceuticals (IONS) stake by 64% in Q1 2026, selling an estimated $7.1M and leaving 50,000 shares worth $3.75M. The position accounts for 0.01% of the portfolio, ranked #796.

Adage Capital Partners first reported a position in IONS in Q3 2023 and has held it in 11 quarters since. The position peaked at $150M in Q2 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Adage Capital Partners held 50,000 shares of Ionis Pharmaceuticals worth $3.75M as of Q1 2026.
Adage Capital Partners sold 90,000 Ionis Pharmaceuticals shares in Q1 2026, an estimated $7.1M.
Ionis Pharmaceuticals made up 0.01% of Adage Capital Partners's portfolio in Q1 2026, its #796 holding.
Adage Capital Partners first reported a position in Ionis Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Adage Capital Partners's Ionis Pharmaceuticals position peaked at $150M in Q2 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.